Raymond James raised the firm’s price target on Knight Therapeutics to C$7.50 from C$7 and keeps an Outperform rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KHTRF:
- Knight Therapeutics Announces Launch of Minjuvi® in Brazil
- Knight Therapeutics initiated with an Outperform at Raymond James
- Knight Therapeutics Inc. Celebrates its First Decade of Success
- Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
- Knight Therapeutics announces launch of Bijuva in Canada